Ticker Hub
ESPR — AI Analysis & Sentiment
4 recent AI-generated analyses for ESPR. Sentiment and confidence insights updated continuously.
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
Esperion's presentation of positive clinical data for bempedoic acid is a bullish signal for its core product, but the company's weak financial hea...
May 26, 2026Esperion to be Acquired by ARCHIMED
Esperion's definitive acquisition by ARCHIMED offers a substantial premium to shareholders, resolving the company's challenging financial situation...
May 1, 2026Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Esperion reported robust Q4 and full year 2025 financial results, showing strong revenue growth and a shift to profitability in the fourth quarter....
Mar 10, 2026Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion announced its acquisition of Corstasis Therapeutics, which includes the FDA-approved Enbumyst nasal spray. This acquisition could signific...
Mar 3, 2026